Flibanserin Online

How and where to order Flibanserin (Addyi) 100 mg tablets online on NCCME website:

Prices:from $6.01 per pill
Discount:5% coupon: 5OFF
Forms:Flibanserin (Addyi) 100 mg tablets
Quantity:12, 20, 32, 60, 92, 120 pills
Type:Flibanserin brand, Fliban brand, Addyi generic
Payment:Visa, Mastercard, AmEx, Bitcoin
Delivery:Standard airmail and trackable courier service
Shipping:Worldwide, including USA, UK, Europe, Canada, Australia

Flibanserin (trade names include Addyi, Fili, Fliban, Pink Viagra) is a gynecological medication for systemic use. It is used for the treatment of pre-menopausal women with hypoactive sexual desire disorder (HSDD). This medicine works related to the Kinsey dual control model of sexual response.

Addyi (Flibanserin) tablets 100 mg

Related medications:

  • Anastrozole (Arimidex)
  • Atosiban (Antocin, Tractocile)
  • Butylscopolamine (Buscopan)
  • Cabergoline (Dostinex)
  • Clomiphene (Clomid)
  • Cyproterone, Ethinyl Estradiol (Diane-35)
  • Danazol (Danocrine)
  • Desogestrel, Ethinyl Estradiol (Desogen)
  • Diazepam (Valium)
  • Eflornithine (Vaniqa)
  • Estradiol (Estrace)
  • Estrogens conjugated (Premarin)
  • Ethinyl Estradiol, Levonorgestrel (Alesse)
  • Exemestane (Aromasin)
  • Ibandronae (Boniva)
  • Letrozole (Femara)
  • Medroxyprogesterone (Cycrin)
  • Norethindrone (Norlutate)
  • Norethisterone (Aygestin)
  • Progesterone (Prometrium)
  • Sildenafil (Female Viagra)
  • Tibolone (Tibofem)

    Pharmacological and medical categories:

  • Central nervous system agents
  • Gynecological drugs
  • Sexual dysfunction medications
  • Treatment of hypoactive sexual desire disorder among women

    ATC codes:

  • G - Genito urinary system and sex hormones
  • G02 - Other gynecologicals
  • G02C - Other gynecologicals
  • G02CX - Other gynecologicals
  • G02CX02 - Flibanserin

    ICD-10 codes:

  • Sexual dysfunction not due to a substance or known physiological condition - F52
  • Hypoactive sexual desire disorder - F52.0

    Indications and usage:

    Addyi (Flibanserin) is indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOTdue to:

  • A co-existing medical or psychiatric condition,
  • Problems within the relationship, or
  • The effects of a medication or other drug substance.

    Limitations of use:

  • Addyi (Flibanserin) is not indicated for the treatment of HSDD in postmenopausal women or in men.
  • This medication is not indicated to enhance sexual performance.

    Dosage and administration:

  • Recommended dosage is 100 mg taken once daily at bedtime.
  • Flibanserin (Addyi) is dosed at bedtime because administration during waking hours increases risks of hypotension, syncope, accidental injury, and central nervous system (CNS) depression.
  • Discontinue treatment after 8 weeksif no improvement.

    Dosage forms and strengths:

    Addyi (Flibanserin) oral tablets 100 mg.


    Overdosage of flibanserin may cause an increase in the incidence or severity of any of the reported adverse reactions. In the event of overdosage, treatment should address the symptoms and supportive measures, as needed. There is no known specific antidote for Addyi.


  • Moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors.
  • Hepatic impairment.

    Warnings and precautions:

  • Hypotension and syncope with ADDYI alone: patients with pre-syncope should immediately lie supine and promptly seek medical help if symptoms do not resolve.
  • Central nervous system (CNS) depression (e.g., somnolence, sedation): can occur with flibanserin alone. Exacerbated by other CNS depressants, and in settings where Addyi concentrations are increased. Patients should avoid activities requiring full alertness (e.g., operating machinery or driving) until at least 6 hours after each dose and until they know how this medication affects them.

    Adverse reactions, side effects:

    Most common adverse reactions (incidence >= 2%) are dizziness, somnolence, nausea, fatigue, insomnia, and dry mouth.

    Drug interactions:

  • Oral contraceptives and other weak CYP3A4 inhibitors: increases flibanserin exposures and incidence of adverse reactions.
  • Strong CYP2C19 inhibitors: increases flibanserin exposure which may increase risk of hypotension, syncope, and CNS depression.
  • CYP3A4 inducers: use of Addyi not recommended; flibanserin concentrations substantially reduced.
  • Digoxin: increases digoxin concentrations, which may lead to digoxin toxicity. Increase monitoring of digoxin concentrations.

    Use in specific populations:

  • Nursing Mothers: flibanserin is not recommended.
  • CYP2C19 poor metabolizers: increases Addyi exposure which may increase risk of hypotension, syncope, and CNS depression.

    Pregnancy categories:

  • B3 - Australia
  • C - United States (Risk cannot be ruled out)

    Salts and other forms:

  • Flibanserin Base
  • Flibanserin Hydrochloride

    Synonyms, international and chemical names:

  • Flibanseriini
  • Flibanserina
  • Flibanserinum
  • Flibanseryna
  • Flibanzerin

    Brands, generics, trade names:

  • Addyi - Sprout Pharmaceuticals
  • Fili - RSM Enterprises
  • Fliban - Centurion Laboratories
  • Pink Viagra - Pfizer


  • Flibanserin main article on Wikipedia: https://en.wikipedia.org/wiki/Flibanserin
  • Flibanserin compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Flibanserin
  • Flibanserin Hydrochloride compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Flibanserin-hydrochloride
  • Flibanserin on DrugBank: https://www.drugbank.ca/drugs/DB04908
  • Flibanserin Hydrochloride on DrugBank: https://www.drugbank.ca/salts/DBSALT001321
  • Flibanserin FAQ on MedlinePlus (revised 11/15/2019): https://medlineplus.gov/druginfo/meds/a615040.html
  • Addyi (Flibanserin) film-coated tablets drug label info on DailyMed (revised October 10, 2019): https://dailymed.nlm.nih.gov/dailymed/drugInfo...
  • Flibanserin for sale on Pharma Doctor (revised September 2021): https://pharma-doctor.com/flibanserin.html
  • Addyi (Flibanserin) oral tablets 100 mg official prescribing information and medication guide from the U.S. FDA (revised 8/2015): https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Addyi (Flibanserin) tablets for oral use full prescribing and patient counseling information from Sprout Pharmaceuticals, Inc. (revised 10/2019): https://addyi.com/wp-content/uploads/2019/11/Full-Prescribing-Information-1.pdf
  • Addyi (Flibanserin) tablets official website: https://addyi.com/
  • Sprout Pharmaceuticals, Inc. (manufacturer and distributor of Addyi) official website: https://sproutpharmaceuticals.com/
  • Addyi (Flibanserin) product monograph and patient medication information from canadian drug and health product register (revised February 27, 2018): https://pdf.hres.ca/dpd_pm/00044049.PDF
  • Addyi (Flibanserin) health fact sheet on NWHN: https://nwhn.org/addyi-health-fact-sheet/
  • Fili (Flibanserin, Addyi generic) 100 mg tablets medication guide from RSM Enterprises pharmaceutical company: https://www.rsmenterprises.in/product/viewdetail/fili-100mg-229

    Revised: September 2021

    Home | About Us | Erlotinib | Flibanserin | Luliconazole | Tolvaptan | Udenafil | FAQ | Contact Us

    Copyright © 2006 - 2021 The National Commission for Certification of CME Professionals, Inc. (NCCME, NC-CME). All rights reserved.